HeartFlow Raises 2026 Revenue Guidance Following Strong Third Quarter Results
HeartFlow (HTFL) reported strong third-quarter 2026 results, highlighted by a 57% year-over-year revenue increase to $72.9 million. Driven by the adoption of its AI-powered FFRct and Plaque Analysis tools, the company raised its full-year revenue guidance to a range of $262 million to $264 million. High-margin software sales helped push non-GAAP gross margins to 83.8%. The company is focusing on long-term expansion through new clinical trials targeting asymptomatic patients, which could expand its total addressable market (TAM) from $5 billion to $11 billion. Management expects to begin reporting data from these trials by late 2028 and aims to achieve cash flow profitability by mid-2028, supported by a strong cash position of $253 million.
Tickers: $HTFL
Topics: artificial intelligence clinical trials earnings report medical technology revenue guidance